In both human and mouse models of colorectal cancers (CRC), Katlinski and colleagues demonstrated that IFNAR1 loss plays a key role in the establishment of an intra- tumoral immune privileged niche in the CRC TME and may be predictive of CRC patient outcomes [95]. This evidence concerns the gene IFNAR1 and colorectal carcinoma.